Volatile Week, but Green? Click to watch the new Podcast.

$0.59 (0.70%)

Volume: 1.577M

Closed: Jul 01, 2022

Hollow Logo Score: -1.185

Ardelyx Stock Forecast

$0.59 (0.70%)

Volume: 1.577M

Closed: Jul 01, 2022

Score Hollow Logo -1.185

Ardelyx Company Profile

34175 Ardenwood Boulevard

Fremont CA 94555



Industry: Biotechnology

Sector: Healthcare



Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic therapeutics for the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome, as well as in Phase IIb clinical trial for the treatment of hyperphosphatemia or elevated serum phosphorus levels in patients with end-stage renal disease. The company is also developing RDX022, an oral, non-absorbed potassium-binder for the treatment of hyperkalemia or elevated serum potassium. Its drug candidates in earlier stages of research and development include RDX009, a secretagogue of glucagon-like peptide-1 and glucagon-like peptide-2; and RDX013, a small molecule drug candidate for hyperkalemia. It has a collaboration partnership with AstraZeneca AB for the development and commercialization of tenapanor; and option and license agreement with Sanofi SA to conduct research for evaluating small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in CKD patients on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE